newsfilter
← Latest News
GlobeNewswire·

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

JBIO
  • Jade Biosciences, Inc. announced that its Board granted an equity award to Edward R. Conner, M.D., effective April 22, 2026, in connection with his appointment as Chief Medical Officer.
  • The Board granted Dr. Conner non-qualified stock options to purchase 500,000 shares under the Employment Inducement Stock Incentive Plan to induce his employment per Nasdaq Listing Rule 5635(c)(4).
  • The stock options carry an exercise price of $25.38 per share, matching the closing price on The Nasdaq Global Market on April 22, 2026.
  • Vesting occurs over four years with 25% vesting on the one-year anniversary & the remaining balance vesting in 36 successive equal monthly installments subject to continued employment.
  • Jade intends to file a Form S-8 registration statement with the U.S. Securities and Exchange Commission to register the shares issuable under the Inducement Plan.
  • Jade Biosciences is a clinical-stage biotechnology company developing therapies for autoimmune diseases, including lead candidate JADE101 for immunoglobulin A nephropathy.
  • The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, & JADE301, an undisclosed antibody candidate.
  • Jade was launched with assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.